Industry News
Biotechnology Industry News
Carlyle’s acquisition of Abingworth brings $2 billion to fuel life science investments
Carlyle's acquisition of Abingworth brings $2 billion to fuel life science investments mbayer Tue, 04/12/2022 - 10:05
Aeglea’s search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%
Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30% ntaylor Tue, 04/12/2022 - 06:11
Eyes on the prize: Aurion Biotech raises $120M for ‘global transformation in the cornea’
Eyes on the prize: Aurion Biotech raises $120M for 'global transformation in the cornea' gmasson Mon, 04/11/2022 - 21:57
Gilead’s CD47 trials freed of FDA hold—for the most part
Gilead’s CD47 trials freed of FDA hold—for the most part mbayer Mon, 04/11/2022 - 17:23
Liver enzyme might hold the secret to new obesity treatments
Liver enzyme might hold the secret to new obesity treatments ssorensen Mon, 04/11/2022 - 16:29
AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target
AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target aarmstrong Mon, 04/11/2022 - 14:58
AACR: BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy data
AACR: BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy data aarmstrong Mon, 04/11/2022 - 10:42
Early wrap up for Veru’s COVID trial spurs doubling of share price, race to regulators
Early wrap up for Veru's COVID trial spurs doubling of share price, race to regulators mbayer Mon, 04/11/2022 - 10:35
With $300M up for grabs, Engitix helps Takeda dig into extracellular matrix in search of IBD drugs
With $300M up for grabs, Engitix helps Takeda dig into extracellular matrix in search of IBD drugs ntaylor Mon, 04/11/2022 - 03:52
FDA’s Califf on accelerated approval: ‘In God, we trust, everyone else must bring good evidence’
FDA's Califf on accelerated approval: 'In God, we trust, everyone else must bring good evidence' mbayer Fri, 04/08/2022 - 15:19
FDA’s Robert Califf on accelerated approval: ‘In God, we trust, everyone else must bring good evidence’
FDA's Robert Califf on accelerated approval: 'In God, we trust, everyone else must bring good evidence' mbayer Fri, 04/08/2022 - 15:19
AACR: C4’s multiple myeloma data prompts dosing switch, giving patients a longer treatment reprieve
AACR: C4's multiple myeloma data prompts dosing switch, giving patients a longer treatment reprieve aarmstrong Fri, 04/08/2022 - 10:42
AACR: C4’s multiple myeloma data prompt dosing switch, giving patients a longer treatment reprieve
AACR: C4's multiple myeloma data prompt dosing switch, giving patients a longer treatment reprieve aarmstrong Fri, 04/08/2022 - 10:42
Cut the music: Kaleido calls it quits after FDA crackdown thwarted its pipeline plans
Cut the music: Kaleido calls it quits after FDA crackdown thwarted its pipeline plans mbayer Fri, 04/08/2022 - 10:38
In just 72 words, BioCryst pauses enrollment for 3 mid-stage trials and sends shares tumbling
In just 72 words, BioCryst pauses enrollment for 3 mid-stage trials and sends shares tumbling aarmstrong Fri, 04/08/2022 - 09:57
In just 72 words, BioCryst pauses enrollment for 3 midstage trials and sends shares tumbling
In just 72 words, BioCryst pauses enrollment for 3 midstage trials and sends shares tumbling aarmstrong Fri, 04/08/2022 - 09:57
AACR: Blueprint wants to make resistance to AstraZeneca’s Tagrisso futile in lung cancer
AACR: Blueprint wants to make resistance to AstraZeneca's Tagrisso futile in lung cancer aarmstrong Fri, 04/08/2022 - 08:41
Genfit bounces back from omicron to keep phase 3 trial on track
Genfit bounces back from omicron to keep phase 3 trial on track ntaylor Fri, 04/08/2022 - 07:32
Final Aduhelm coverage decision keeps the door cracked open for Alzheimer’s therapies to come
Final Aduhelm coverage decision keeps the door cracked open for Alzheimer's therapies to come aarmstrong Fri, 04/08/2022 - 07:28
GenSight seeks cash as runway enters final year with gene therapy still stuck at EMA
GenSight seeks cash as runway enters final year with gene therapy still stuck at EMA ntaylor Fri, 04/08/2022 - 06:44